Gyros' open and flexible platform for quantitative protein analysis is perfectly suited to the specific analytical needs associated with process development and clinical evaluation of therapeutic proteins such as monoclonal antibodies.

Gyrolab offers unique advantages and improved effectiveness for all your screening and quantification applications during protein-drug development – from early screening of drug candidates to the completion of clinical trials.

In addition to generating high-qualitative and reliable results, Gyrolab is able to meet assay development, transferability and scale-up requirements, helping to shorten timelines during each phase of biotherapeutic development.